Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093901 | 0.89 | KMT2A (0.45) | CYP1A2CYP2D6CYP3A4TP53MAPT | |
| SCHEMBL7392174 | 0.81 | TP53 (0.52) | CYP1A2TP53MAPTKMT2AMEN1 | |
| SCHEMBL6094949 | 0.80 | TP53 (0.40) | TP53MAPTKMT2AMEN1HTT | |
| SCHEMBL6093868 | 0.80 | TP53 (0.40) | TP53MAPTKMT2AMEN1HTT | |
| SCHEMBL6093303 | 0.80 | HRH3 (0.37) | CYP1A2CYP2D6CYP3A4TP53MAPT | |
| SCHEMBL6096109 | 0.80 | TP53 (0.39) | TP53MAPTKMT2AMEN1HTT | |
| SCHEMBL7363009 | 0.80 | TP53 (0.55) | CYP1A2TP53MAPTKMT2AMEN1 | |
| SCHEMBL6095531 | 0.79 | MAPT (0.43) | TP53MAPTKMT2AMEN1HTT | |
| SCHEMBL6095405 | 0.79 | HRH3 (0.47) | TP53MAPTHTTSMN1; SMN2GAA | |
| SCHEMBL5735674 | 0.79 | MAPT (0.43) | TP53MAPTKMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109351-B1 | Fused pyrrolecarboxamides; GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-19 | — | — | US | claimed |
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION | 2005-01-20 | — | — | US | claimed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | claimed |
| EP-1210328-A1 | FUSED PYRROLECARBOXAMIDES: A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-06-05 | — | — | EP | claimed |
| US-20010029299-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN | 2001-10-11 | — | — | US | claimed |
| WO-2001016103-A1 | FUSED PYRROLECARBOXAMIDES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2001-03-08 | — | — | WO | claimed |
| US-7109351-B1 | Fused pyrrolecarboxamides; GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
| US-6515140-B2 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators; drug abruse | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-20010029299-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN | 2001-10-11 | — | — | US | disclosed |
| US-6211365-B1 | BRAIN DISORDERS | NEUROGEN CORPORATION | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | GABRB2, GABRB1, GABRB3 | CYP1A2 276/4885CYP2D6 524/4885CYP3A4 254/4885 |
| US-20010029299-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | CYP1A2 320/4885CYP2D6 213/4885CYP3A4 271/4885 |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | CYP1A2 279/4885CYP2D6 209/4885CYP3A4 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.